J&J vaccine deal to boost Aspen's global profile
The deal with Johnson & Johnson will also be a boost for exports and create an inflow of foreign currency
08 November 2020 - 00:00
The Covid-19 vaccine deal Aspen has secured with Johnson & Johnson may not yield new direct jobs but will position SA as a major player in the international pharmaceutical industry and provide Aspen with a higher international profile to secure further deals.
“SA is not known to be a pharmaceutical destination. It is expected from Europe and Asia,” Stavros Nicolaou, group senior executive for strategic trade at Aspen Pharma Group, said this week...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.